Clinical trials: Advanced Intestinal Cancer
Colorectal Neoplasm
Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
This trial is being performed in two parts: Dose Escalation and Dose Expansion. The primary objective for the Dose Escalation part is to determine the safety and tolerability at different doses of DS-8273a administered in…
- Trial name
- NCT02991196
- Testing
- DS-8273a + nivolumab
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Daiichi Sankyo
Rectal Neoplasms
Study for Wait and Watch Suitable in Rectal Cancer
One of the standard treatment options offered to patients of locally advanced rectal cancer is neoadjuvant (treatment given before surgery) radiotherapy \& chemotherapy followed by surgery.
- Trial name
- ARROW (NCT06252142)
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Tata Memorial Centre
Rectal Cancer
Prediction of the Response to Neoadjuvant Radiation Chemotherapy Through Texture Analysis Derived From Medical Imaging
In patient with complete pathological response, surgery could be omitted without compromising progression-free or overall survival. A powerful prediction model is needed to guide management of this population.
- Trial name
- RECTOMICS (NCT04920435)
- Where
- 3 sites in France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Brest
Colorectal Cancer
S9923 R115777 in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have recurrent or…
- Trial name
- NCT00005833
- Testing
- R115777
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
- Trial name
- FRUITION (NCT06992258)
- Testing
- Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Criterium, Inc.
Advanced Cancer, Metastatic Cancer
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
- Trial name
- NCT03785249
- Testing
- MRTX849, Pembrolizumab, Cetuximab
- Where
- 222 sites in United States, Puerto Rico
- Volunteers
- 731 people
- Sponsor
- Mirati Therapeutics Inc.
Probiotics Plus Chemotherapy
Probiotics Combined With Chemotherapy for Patients With Advanced NSCLC
Based on the theory of intestinal lung axis, the effect of new therapy on patients with advanced NSCLC was observed by adjusting the intestinal micro-ecology and combining existing platinum-based doublet chemotherapy.
- Trial name
- NCT03642548
- Testing
- bifico
- Volunteers
- 180 people
- Sponsor
- Shanghai 10th People's Hospital
Rectum Cancer, Adenocarcinoma
ADAR1 Expression Level in Rectal Cancer
Total neoadjuvant therapy (TNT) is currently the standard treatment for locally/locally advanced rectal cancer due to better response and fewer distant metastases.
- Trial name
- ADAR1TNT (NCT07108348)
- Testing
- Adenosine deaminase acting on RNA1
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Necmettin Erbakan University
Colorectal Cancer
IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure
The primary objective of the Phase I part of the study is to determine the recommended dose of capecitabine to be administered in combination with ZD1839 250 mg orally once daily in subjects with advanced or metastatic colorectal…
- Trial name
- NCT00242788
- Testing
- Gefitinib and capecitabine
- Where
- 6 sites in Spain
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Metastatic Colorectal Cancer
Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC
This phase II study aims to explore the efficacy and safety of fruquintinib combined with TAS-102 in the third-line treatment of patients with advanced metastatic colorectal cancer.
- Trial name
- NCT05004831
- Testing
- fruquintinib plus TAS-102
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Bladder Cancer, Head and Neck Squamous Cell Carcinoma
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer.
- Conditions
- Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer
- Trial name
- VISTA (NCT03740256)
- Testing
- CAdVEC
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Baylor College of Medicine
Colorectal Cancer
AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: AZD2281 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00535353
- Testing
- irinotecan hydrochloride, olaparib
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- NCIC Clinical Trials Group
Lymphoma, Small Intestine Cancer
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00005639
- Testing
- Azacitidine Injection, sodium phenylbutyrate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma, Lymphoproliferative Disorder
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
RATIONALE: KX2-391 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of KX2-391 in treating patients with advanced…
- Conditions
- Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00646139
- Testing
- Src kinase inhibitor KX2-391, immunoenzyme technique, pharmacological study
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Chemo-refractory Colorectal Carcinoma
D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer
This is a phase I/II-trial with D,L-methadone and mFOLFOX6 in the treatment of patients with histologically confirmed chemo-refractory colorectal carcinoma.
- Trial name
- MEFOX (NCT05212012)
- Testing
- Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)
- Where
- 3 sites in Germany
- Volunteers
- 11 people
- Sponsor
- AIO-Studien-gGmbH
Esophageal Cancer, Gastric Cancer
Irinotecan in Treating Patients With Advanced Cancer of the Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have advanced…
- Trial name
- NCT00003137
- Testing
- irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma (Skin), Melanoma
Pembrolizumab and EDP1503 in Advanced Melanoma
This study is being done to determine if orally administered EDP1503 will enhance the response to standard immunotherapy treatment (pembrolizumab) in participants with advanced melanoma.
- Trial name
- NCT03595683
- Testing
- Pembrolizumab, EDP1503
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Chicago
Colorectal Neoplasms, Metastases
Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer
The purpose of this study is to evaluate the feasibility and efficacy of first-line FOLFIRI discontinuation after initial 8 cycles and reintroduction after progression.
- Trial name
- NCT00320320
- Testing
- Irinotecan
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Gachon University Gil Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.